Telo Genomics Corp. TDSGF
Set alert
0.04 USD 0.00 0.00%
At close · Oct 30
0.036 Day range 0.036
0.018 52-week range 0.065
- YTD
- -28.00%
- 1 year
- -5.26%
- Open
- 0.036
- Prev close
- 0.036
- Mkt cap
- 3.62M
- Vol
- 10.00K
- Avg vol
- 9.28K
- EPS
- -0.02
- P/E
- 0.00
More statistics
- Low
- 0.036
- High
- 0.036
3M chart
Signals (25)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 21, 2026 | 1 week ago |
| RSI: Overbought | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 4 weeks ago |
| SMA: Bullish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 29, 2026 | 1 month ago |
| SMA: Bullish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 23, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 4, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 2 months ago |
| SMA: Bullish | Sep 3, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
Newest 20 of 25.
News
- TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing
- Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
- Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse
- Telo Genomics Grants Stock Options
- Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment
- Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma
- Telo Genomics Announces Termination of Investor Relations Agreement
- Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
- Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman
- Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing
Your note
Sign in to keep a note on TDSGF — it syncs with the Stock Master app.